What Is PFAS

PFAS (per- and polyfluoroalkyl substances) are a large family of synthetic chemicals characterized by chains of carbon atoms bonded to fluorine, one of the strongest bonds in organic chemistry. They have been manufactured since the 1940s for use in nonstick coatings, water-repellent fabrics, firefighting foams, and food packaging. Because they resist degradation by heat, water, and biological enzymes, PFAS accumulate in the environment and in living organisms, including humans.

PFAS matter to longevity because their persistence in the body means that even low-level chronic exposure results in measurable tissue accumulation over a lifetime. Epidemiological studies have linked elevated PFAS blood levels to disrupted thyroid function, altered cholesterol metabolism, reduced vaccine antibody response, increased risk of certain cancers (particularly kidney and testicular), and impaired reproductive health. The mechanisms behind these associations involve interference with hormone receptor signaling, disruption of lipid transport pathways, and suppression of immune cell function.

From an aging perspective, PFAS exposure compounds the burden that other environmental toxins place on the body's detoxification and repair systems. The liver, which is the primary organ responsible for metabolizing foreign chemicals, handles PFAS inefficiently because the carbon-fluorine bond resists the cytochrome P450 enzyme system that processes most xenobiotics. This means PFAS occupy detoxification capacity without being cleared, potentially slowing the processing of other harmful substances and contributing to the concept of total body burden. For anyone focused on extending healthspan, understanding and reducing PFAS exposure represents one of the more actionable environmental levers available.

PFAS enter the body primarily through ingestion of contaminated water or food, though inhalation and skin absorption also contribute. Once absorbed from the gastrointestinal tract, PFAS bind to serum albumin and other proteins in the blood, which distributes them to tissues throughout the body. They concentrate particularly in the liver, kidneys, and blood. Unlike most organic pollutants that dissolve in fat, many PFAS are amphiphilic (attracted to both water and fat), which gives them a unique distribution pattern and allows them to interact with cell membranes and protein surfaces in ways that purely lipophilic toxins do not.

The biological harm from PFAS appears to stem from several overlapping mechanisms. PFAS molecules structurally resemble fatty acids, allowing them to bind to peroxisome proliferator-activated receptors (PPARs) and other nuclear receptors that regulate lipid metabolism, glucose homeostasis, and inflammation. This molecular mimicry can alter gene expression in the liver, shifting cholesterol and triglyceride handling in ways that elevate serum lipids. PFAS also interfere with thyroid hormone transport by competing for binding sites on transthyretin, a key carrier protein, which can reduce circulating levels of free thyroid hormones. In the immune system, PFAS suppress antibody production by B cells, an effect documented in studies measuring vaccine response in exposed populations.

The body's primary route for PFAS elimination is through bile excretion into the intestine, but extensive enterohepatic recirculation (reabsorption from the gut back into the blood) dramatically slows this process. The kidneys also filter some PFAS, but renal tubular reabsorption reclaims much of what is filtered. The net result is a biological half-life measured in years rather than days, distinguishing PFAS from most other environmental chemicals the body encounters.

PFAS exposure does not produce a distinct clinical syndrome at typical environmental levels, which is part of what makes it insidious. Instead, the effects manifest as shifts in common biomarkers that are often attributed to other causes. Elevated total cholesterol and LDL that do not respond well to dietary changes may reflect PFAS-mediated disruption of hepatic lipid metabolism. Subclinical hypothyroidism, characterized by mildly elevated TSH with borderline-low free T4, can be another signal, particularly in individuals without other obvious thyroid risk factors.

Immune effects may appear as unusually poor responses to vaccines or increased susceptibility to infections, though these are difficult to distinguish from other causes without laboratory context. In women, PFAS exposure has been associated with reduced fecundity and pregnancy complications including preeclampsia, while in men, associations with reduced semen quality have been observed. None of these signs are specific to PFAS, which is why laboratory testing is necessary to establish whether PFAS burden is a contributing factor in any individual case.

Serum blood testing is the standard method for assessing individual PFAS body burden. Panels typically measure four to seven specific compounds, with PFOS and PFOA being the most commonly reported. Several clinical laboratories offer PFAS panels, and environmental medicine practitioners can order them. Results are reported in nanograms per milliliter (ng/mL) and can be compared to population reference values from national biomonitoring programs. The National Academies report proposed clinical guidance levels to help interpret results in the context of health risk.

Water testing is equally important for identifying ongoing exposure sources. Certified laboratories can test tap water for a range of PFAS compounds, with results compared against EPA health advisory levels. Some municipalities publish their own PFAS monitoring data, which can provide a starting point before investing in private testing. For a comprehensive picture, combining serum testing with water and household product audits gives the clearest view of both accumulated burden and active exposure routes.

Remediation of PFAS exposure begins with source elimination, since the body's slow clearance rate means that reducing intake has a larger near-term impact than any detoxification protocol. Water filtration is the highest-priority intervention for most households. Reverse osmosis systems consistently remove over 90 percent of tested PFAS compounds; granular activated carbon filters are also effective, though performance varies by filter medium and contact time. Point-of-use systems installed at the kitchen tap are more practical than whole-house systems for most people and address the primary ingestion route.

Beyond water, replacing nonstick cookware, avoiding stain-resistant fabric treatments, and choosing PFAS-free food packaging all reduce daily intake. Cosmetics and personal care products are an emerging source; products labeled "PTFE-free" or "fluoro-free" are preferable when alternatives exist.

For individuals with documented high serum levels, clinical strategies focus on interrupting enterohepatic recirculation. Cholestyramine, a bile acid sequestrant, binds substances in the gut lumen and prevents their reabsorption, and some environmental medicine clinicians use it off-label for this purpose. Increasing dietary fiber may support bile excretion through a similar, gentler mechanism. Regular blood or plasma donation has been associated with modestly lower PFAS levels in observational data, likely by physically removing protein-bound PFAS from circulation. These approaches are best undertaken with clinical guidance, as the evidence base for each remains preliminary.

The epidemiological evidence linking PFAS to adverse health outcomes is substantial, drawn from occupational cohort studies (workers at PFAS manufacturing plants), community studies near contaminated sites, and large population surveys like NHANES. The strongest associations are with elevated serum cholesterol, thyroid disease, reduced vaccine antibody response, kidney cancer, and testicular cancer. These associations led an expert panel evaluating residents near a DuPont facility to conclude that there was a "probable link" between PFOA exposure and six disease categories. The National Academies of Sciences, Engineering, and Medicine published a consensus report evaluating the weight of evidence and classifying several health effects by strength of association.

However, significant gaps remain. Most research has focused on legacy PFAS like PFOS and PFOA, while thousands of newer replacement compounds (such as GenX) have far less toxicological data. Mechanistic studies in animals support the epidemiological findings but often use doses higher than typical human exposures, making dose-response extrapolation uncertain. Evidence for specific detoxification interventions in humans is limited: cholestyramine has biological plausibility for interrupting enterohepatic recirculation, but no large randomized trial has confirmed its efficacy for PFAS clearance specifically. Blood and plasma donation has been observed to reduce PFAS levels in some studies, likely because it removes PFAS bound to serum proteins, but this is not an established medical recommendation for detoxification.

PFAS exposure is essentially universal in industrialized populations, so the relevant question is the degree of burden rather than whether exposure has occurred. Individuals living near known contamination sites, military personnel exposed to AFFF, and workers in fluorochemical manufacturing face substantially higher risks. Testing and remediation should be guided by a practitioner knowledgeable in environmental medicine, as PFAS management involves nuanced interpretation of serum levels, consideration of co-exposures, and careful selection of interventions that have plausible mechanisms rather than unvalidated commercial detox products.